Neurology and therapy Abdelnour, C., Gonzalez, M. Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022.View details for PubMedCentralID PMC10272890
#Carla gonzalez vargas trial#
This is relevant for future clinical trial designs. MDS-UPDRS part III showed nearly identical annual changes (DLB 4.8 ) (PDD 4.8, ).DLB and PDD showed similar rates of cognitive and motor decline. There is a need to better understand the rate of cognitive and motor decline of Dementia with Lewy bodies (DLB) and Parkinson's disease Dementia (PDD).To compare the rate of cognitive and motor decline in patients with DLB and PDD from the E-DLB Consortium and the Parkinson's Incidence Cohorts Collaboration (PICC) Cohorts.The annual change in MMSE and MDS-UPDRS part III was estimated using linear mixed regression models in patients with at least one follow-up (DLB n = 837 and PDD n = 157).When adjusting for confounders, we found no difference in the annual change in MMSE between DLB and PDD (-1.8 vs. J., Rejdak, K., Papuc, E., Hort, J., Nedelska, Z., O'Brien, J., Bonanni, L., Marquié, M., Boada, M., Pytel, V., Abdelnour, C., Alcolea, D., Beyer, K., Tysnes, O. E., Paquet, C., DeLena, C., D'Antonio, F., Pilotto, A., Padovani, A., Blanc, F., Falup-Pecurariu, C., Lewis, S. H., Camacho, M., Forsgren, L., Bäckström, D., Lawson, R. A., Alves, G., Dalen, I., Williams-Gray, C. Movement disorders clinical practice Gonzalez, M. Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia.
Use of biomarkers for diagnosis and group stratification in clinical trials of DLB is growing and likely to be of increasing importance in the future.SUMMARY: In vivo biomarkers can enhance patient selection in clinical trials allowing greater diagnostic accuracy, a more homogeneous trial population, and stratification by co-pathology to create subgroups most likely to derive therapeutic benefit from DMTs. Additionally, validation of plasma phosphorylated tau assays in DLB is ongoing and offers an accessible biomarker to indicate the existence of AD co-pathology. Recent advances in the development of alpha-synuclein seeding amplification assays (SAA) allow accurate identification of alpha-synuclein from the prodromal stages in DLB. The purpose of this review is to describe how recent advances in the development of biofluid biomarkers may be used in clinical trials to tackle some of these challenges.RECENT FINDINGS: Biomarkers are essential both to support the accurate diagnosis of DLB and to delineate the influence of coexisting pathologies. Clinical trials face difficulties due to the clinical and neuropathological heterogeneity of the condition with a diverse array of neuropathogenic mechanisms contributing to the clinical phenotype. PURPOSE OF REVIEW: Currently, no disease modifying therapies (DMTs) have been approved for use in dementia with Lewy bodies (DLB). Additionally, she wants to study the biological underpinnings of prodromal Lewy body disease to identify potential biomarkers for diagnosis and prognosis. As a Sue Berghoff LBD Research Fellow, her plan is to investigate the impact of different comorbidities in the clinical presentation, cognitive profile, and disease progression of Lewy body disease. Carla´s main interest is the study of neurodegenerative diseases, especially Lewy body disease. Her thesis focused on the influence of Alzheimer´s disease copathology in atrophy patterns, longitudinal cognitive decline, and heterogeneity of patients with dementia with Lewy bodies. Dag Aarsland, Javier Pagonabarraga and Jaime Kulisevsky. She conducted her doctorate in Medicine at the Autonomous University of Barcelona working with Drs. Carla Abdelnour received her medical degree at the Central University of Venezuela, and then completed her neurology residency training at the University Hospital Príncipe de Asturias in Madrid, Spain.
Stanford Institute for Economic Policy Research (SIEPR).
0 kommentar(er)
